Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760), a leading medical device company based in China, is poised to acquire a 75% controlling stake in Germany-headquartered in vitro diagnostics (IVD) specialist DiaSys Diagnostic Systems GmbH. The transaction is valued at EUR 115 million (USD 127 million), marking a significant move in the IVD market.
Financial Considerations and Future Investment
In addition to the acquisition cost, Mindray has committed to investing a further EUR 40 million (USD 44 million) into DiaSys upon the deal’s closure. This investment is intended to support the future business development of the acquired company, ensuring its continued growth and innovation in the IVD sector.
DiaSys’ Background and Mindray’s Strategic Integration
Founded in 1991, DiaSys Diagnostic Systems GmbH has established itself as a specialist in the research and development and manufacturing of IVD quality control and calibration materials. With this acquisition, Mindray aims to integrate DiaSys’s global supply chain platform, which will enhance its international presence and capabilities. The move will also allow Mindray to expand its international talent team and accelerate its overseas supply chain construction, enabling the company to better serve medium and large-volume clients on a global scale.-Fineline Info & Tech
